EP-1180: Postoperative IMRT with helical tomotherapy for breast cancer: outcome and toxicity analysis  by Fourquet, J. et al.
ESTRO 35 2016                                                                                                                                                    S561 
________________________________________________________________________________ 
Material and Methods: We prospectively identified all 
patients due to receive adjuvant RT to left breast after 
surgery for early breast cancer, and offered participation. 
After RT planning scan patients were kept in treatment 
position and asked to hold their breath for 20 seconds twice, 
with one minute between attempts. Demographics and 
patient factors were recorded. Treatment was subsequently 
delivered as normal with no breath-holding used. 
 
Results: Fifty-eight patients were included, median age 60.0 
years (range 35.1-85.2), median body mass index 26.8 (18.1-
39.3). WHO Performance status was 0-1 in 56, and 2 in 2 
patients; 3 patients had mobility issues, 2 were unable to 
climb on the scanner couch unaided. Seven patients had a 
diagnosis of chronic respiratory disease, 7 using inhalers 
regularly. Twenty patients were ex-smokers, 7 current 
smokers, 31 never smoked. At diagnosis, 6 patients (10%) had 
ductal carcinoma in-situ, 36 (62%) T1, 15 (26%) T2, and 1 (2%) 
T3 disease; 9 (16%) had nodal disease; 7 (12%) had full 
axillary node clearance and 16 (28%) had chemotherapy prior 
to RT. Fifty three (91%) were successful in breath-holding for 
both 20 second periods, 2 (3%) were unsuccessful on both 
attempts. Two (3%) were unsuccessful first, but successful a 
minute later; 1 (2%) was successful for the first period but 
not the second. 
 
Conclusion: The vast majority of patients from an unselected 
cohort of patients due to undergo adjuvant RT to the breast 
or chest wall were able to maintain breath-hold successfully 
for two 20-second periods one minute apart in a simulated 
treatment position. No consistent patient factors were 
identified that would reliably predict success or failure to 
breath-hold. We anticipate most patients will tolerate 
breath-holding techniques during breast RT should they be 
employed more in the future. In the era of stereotactic 
ablative RT, breath-holding may also become important in 
other patient cohorts. 
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Purpose or Objective: The aim of this study was to 
determine whether PET/MR could predict disease-free 
survival (DFS) in patients with operable breast cancer. 
 
Material and Methods: Seventy-eight patients with breast 
cancer were enrolled. All patients underwent preoperative 
parallel PET/MR: whole body PET/CT at 1 h after 18F-FDG 
injection, breast dynamic contrast enhanced MR, and breast 
PET/CT at 2h after 18F-FDG injection sequentially in prone 
position. All patients were analyzed by diverse parameters 
(maximum SUV at 1 h [SUV1], maximum SUV at 2 h [SUV2], 
retention index of SUVmax [RI], metabolic tumor volume 
[MTV], total lesion glycolysis [TLG], initial slope of the 
enhancement curve [IS], transfer constant [Ktrans], reflux 
constant [Kep], extravascular extracellular space volume 
fraction [Ve], and initial area under the curve [iAUC]) . A 
relationship between covariates and DFS after operation was 
analyzed using Kaplan-Meier method and multivariate Cox 
proportional-hazard regression method. 
 
Results: The median follow-up of 78 patients was 55 months 
(31-67 months), and 9 (11.5 %) patients developed recurrence 
or metastasis. Among parameters, higher RI (p = 0.0010), 
lower Ktrans (p = 0.0046), and lower Ve (p = 0.0035) were 
significantly associated with poorer DFS. In contrast, SUV1, 
SUV2, MTV, TLG, IS, Kep, and iAUC were not. On multivariate 
analysis, RI (p = 0.016; HR = 5.20; CI 1.4-19.7), and Ktrans (p 
= 0.035; HR = 0.22; CI 0.054-0.89) were found as independent 
predictors of DFS. Patients with higher RI and lower Ktrans 
revealed a significantly higher recurrence rate (66.7 %) than 
the rest of patients (6.9 %, P<0.0001). 
 
Conclusion: RI and Ktrans measured by preoperative parallel 
PET/MR can predict DFS in patients with operable breast 
cancer. The combination of these parameters could make 
improvement of patients care because tailored surveillance 
would be applied for high risk group. 
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Purpose or Objective: Radiation therapy (RT) plays a key 
role in the management of breast cancer. Intensity-
modulated radiotherapy (IMRT) has been shown to provide a 
more homogeneous dose distribution and to decrease skin 
toxicity. It covers a wide spectrum of techniques, ranging 
from static IMRT to helical tomotherapy (HT). HT could be 
relevant for complex volumes and/or difficult anatomies, but 
it needs to be evaluated since clinical data are still limited. 
The objective of this retrospective study is to investigate the 
short-term outcome and toxicity in a series of patients 
treated with adjuvant breast HT. 
 
Material and Methods: Patients with an indicated breast 
adjuvant radiotherapy using an IMRT technique were included 
after a staff discussion. The treatment was performed with 
HT with concomitant boost if needed: 50 Gy (2 Gy/fraction) 
over the breast or the chest wall and lymph nodes, 60 Gy (2.4 
Gy/fraction) on the tumor bed, 58 Gy (2.33 Gy/fraction) on 
the mastectomy scar if indicated. Toxicities were evaluated 
according to the NCI-CTCAE v4.0. A search for factors related 
to toxicity was conducted using univariate and multivariate 
analysis. 
 
Results: 98 patients were treated between January 2013 and 
September 2014. The following target volumes were 
irradiated: breast (53.4%) or chest wall (46.6%), locoregional 
lymph nodes i.e. internal mammary chain, infra and 
supraclavicular levels (79.6%). 54.4% of them were treated 
for left side breast cancer. The acute toxicities were mainly 
skin toxicity (grade (gr) 1: 63.1%; gr 2: 28.2%; gr 3: 3.9%) and 
esophagitis (gr 1: 42.9%; gr 2: 15.3%). Other acute toxicities 
were gr 1 laryngitis (2.0%); gr 2 pneumonitis (1.0%); gr 1 
(3.1%) and gr 2 (1.0%) cough. With a median follow-up of 8.4 
months (1.1-20.7), there were skin toxicity (gr 1: 41.2%, gr 2: 
2.1%) and dysphagia (gr 1: 1.0%). No local recurrence 
occurred, two metastatic relapse occurred and one patient 
died (death related to cancer). Factors significantly (p<0.05) 
correlated with toxicity in multivariate analysis were: breast 
size and average skin dose for acute skin toxicity; 
chemotherapy, esophageal D2%, average esophageal dose, 
esophageal V30Gy and V45Gy for esophagitis. For the short-
term skin toxicity, PTV volume, PTV D2% and average PTV 
dose were associated with toxicity. 
 
Conclusion: In this retrospective study with a short follow-
up, postoperative breast HT is a well-tolerated treatment for 
patients in need of a complex irradiation. Several clinical and 
dosimetrical parameters related to toxicity have been 
identified. 
 
 
 
